Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Janux Therapeutics Q3 EPS $(0.39) Beats $(0.60) Estimate, Sales $10.000M Beat $2.929M Estimate

Author: Benzinga Newsdesk | November 06, 2025 05:15pm
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 34.67 percent. This is a 23.53 percent increase over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $10.000 million which beat the analyst consensus estimate of $2.929 million by 241.46 percent. This is a 2.18K percent increase over sales of $439.000 thousand the same period last year.

Posted In: JANX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist